We made use of the EGFRmut NSCLC persister model PC9, which has tunable low or high STAT1 pathway activity in the absence or presence (respectively) of IFNγ stimulation and was used in the initial discovery of the type I PRMT vulnerability in persistent cancer cells (21). This evidence concerns the gene IFNG and non-small cell lung carcinoma.